CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PCCB (ImmuneEditome ID:5096)

1. Gene summary of enriched editing regions for PCCB

check button Gene summary
Gene informationGene symbol

PCCB

Gene ID

5096

GeneSynonyms-
GeneCytomap

3q22.3

GeneTypeprotein-coding
GeneDescriptionpropionyl-CoA carboxylase beta chain, mitochondrial|PCCase subunit beta|propanoyl-CoA:carbon dioxide ligase subunit beta|propionyl CoA carboxylase, beta polypeptide|propionyl Coenzyme A carboxylase, beta polypeptide|propionyl-CoA carboxylase beta subunit
GeneModificationdate20230409
UniprotIDP05166;E7ENC1;E7ETT4;E9PDR0;C9JVW9;C9JQS9;E7EUY3;E7EX59;E7ETT1;C9JVY9;C9JAW3;F8WBI9;E9PEC3
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:136331287-136332088:+ENST00000471595.4ENSG00000114054.12PCCBintronicAluSc,L1MC4,AluSxchr3:136331287-136332088:+.alignment
chr3:136331287-136332088:+ENST00000478469.4ENSG00000114054.12PCCBintronicAluSc,L1MC4,AluSxchr3:136331287-136332088:+.alignment
chr3:136334807-136335739:+ENST00000471595.4ENSG00000114054.12PCCBUTR3(C)n,AluSx1,AluJbchr3:136334807-136335739:+.alignment
chr3:136334807-136335739:+ENST00000478469.4ENSG00000114054.12PCCBUTR3(C)n,AluSx1,AluJbchr3:136334807-136335739:+.alignment


Top

2. Tumor-specific enriched editing regions for PCCB


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:136331287-136332088:+KICHEER1.2796e-02image
ENSG00000114054.12,PCCBKICHEAG1.5733e-02image
chr3:136331287-136332088:+KIRCEER1.5690e-05image
ENSG00000114054.12,PCCBKIRCEAG3.6316e-06image
chr3:136331287-136332088:+LUADEER8.5151e-05image
ENSG00000114054.12,PCCBLUADEAG1.6140e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000114054.12,PCCBKIRPPathEAG2.3088e-023.4160e-020.1346image
chr3:136331287-136332088:+KIRPPathEER2.4340e-023.6353e-020.1330image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for PCCB


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:136331287-136332088:+UVMEERENSG00000174628,IQCK-0.52634.8216e-031.0301e-03-0.4200imageNADAR;ELAVL1;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
chr3:136331287-136332088:+UVMEERENSG00000197249,SERPINA1-0.49469.0570e-037.1394e-04-0.4318imageNNSERPINA1T_cells_CD8GSVA_HALLMARK_COMPLEMENT
chr3:136331287-136332088:+UVMEERENSG00000163584,RPL22L10.48321.0604e-024.4430e-040.4464imageNADAR;ELAVL1;UPF1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr3:136331287-136332088:+UVMEERENSG00000188807,TMEM201-0.47611.2689e-021.9609e-05-0.5290imageNADAR;ELAVL1;UPF1NAMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000129116,PALLD0.44232.0627e-023.3470e-040.4548imageNADAR;ELAVL1;UPF1NAMacrophages_M0GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000100364,KIAA0930-0.44472.2243e-021.7899e-03-0.4014imageNADAR;ELAVL1;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000049449,RCN10.43812.4933e-021.5978e-030.4053imageNADAR;ELAVL1;UPF1NANK_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr3:136331287-136332088:+UVMEERENSG00000137692,DCUN1D50.43322.7135e-024.5056e-040.4460imageNADAR;ELAVL1;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000104413,ESRP10.42153.3747e-022.7904e-040.4601imageNADAR;ELAVL1;UPF1NANK_cells_activatedGSVA_HALLMARK_E2F_TARGETS
chr3:136331287-136332088:+UVMEERENSG00000144381,HSPD10.41763.4376e-021.3472e-030.4111imageNADAR;ELAVL1;UPF1HSPD1NK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000174628,IQCK-0.52634.8216e-031.0301e-03-0.4200imageNADAR;ELAVL1;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
chr3:136331287-136332088:+UVMEERENSG00000197249,SERPINA1-0.49469.0570e-037.1394e-04-0.4318imageNNSERPINA1T_cells_CD8GSVA_HALLMARK_COMPLEMENT
chr3:136331287-136332088:+UVMEERENSG00000163584,RPL22L10.48321.0604e-024.4430e-040.4464imageNADAR;ELAVL1;UPF1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr3:136331287-136332088:+UVMEERENSG00000188807,TMEM201-0.47611.2689e-021.9609e-05-0.5290imageNADAR;ELAVL1;UPF1NAMacrophages_M2GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000129116,PALLD0.44232.0627e-023.3470e-040.4548imageNADAR;ELAVL1;UPF1NAMacrophages_M0GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000100364,KIAA0930-0.44472.2243e-021.7899e-03-0.4014imageNADAR;ELAVL1;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000049449,RCN10.43812.4933e-021.5978e-030.4053imageNADAR;ELAVL1;UPF1NANK_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr3:136331287-136332088:+UVMEERENSG00000137692,DCUN1D50.43322.7135e-024.5056e-040.4460imageNADAR;ELAVL1;UPF1NAT_cells_follicular_helperGSVA_HALLMARK_KRAS_SIGNALING_DN
chr3:136331287-136332088:+UVMEERENSG00000104413,ESRP10.42153.3747e-022.7904e-040.4601imageNADAR;ELAVL1;UPF1NANK_cells_activatedGSVA_HALLMARK_E2F_TARGETS
chr3:136331287-136332088:+UVMEERENSG00000144381,HSPD10.41763.4376e-021.3472e-030.4111imageNADAR;ELAVL1;UPF1HSPD1NK_cells_restingGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

4. Enriched editing regions and immune related splicing for PCCB


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000114054.12,PCCB
COADEAGIRENSG00000138031.10chr224826044:24826126:24827545:248276080.25924.7153e-025.7583e-120.4683imageNACIN1;ADAR;AIFM1;ALYREF;AUH;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr3:136331287-136332088:+
ESCAEERA3ENSG00000087088.15chr1948960809:48960914:48961482:48961636:48961276:48961636-0.15472.2106e-021.5069e-05-0.4180imageNADAR;ELAVL1;UPF1BAXGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr3:136331287-136332088:+
THYMEERIRENSG00000079950.9chr6132471462:132471600:132472281:132472375-0.39778.9191e-031.4435e-04-0.4099imageNADAR;ELAVL1;UPF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000114054.12,PCCB
THYMEAGIRENSG00000125458.2chr1775130224:75130867:75130964:75131081-0.39962.1809e-022.2239e-05-0.4356imageNAIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMast_cells_restingGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000114054.12,PCCB
THYMEAGIRENSG00000185504.12chr1781539884:81540950:81541308:815413950.43211.6972e-021.7848e-050.4401imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MTORC1_SIGNALING
chr3:136331287-136332088:+
THYMEERESENSG00000125354.18chrX119618712:119618786:119625334:119625396:119629317:119629508-0.32651.7665e-021.3250e-07-0.5883imageNADAR;ELAVL1;UPF1SEPT6Mast_cells_restingGSVA_HALLMARK_E2F_TARGETS
ENSG00000114054.12,PCCB
THYMEAGA3ENSG00000089022.9chr12111867571:111867669:111870270:111870307:111868752:1118703070.37182.6010e-022.0862e-050.4415imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184MAPKAPK5Mast_cells_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr3:136331287-136332088:+
THYMEERIRENSG00000185504.12chr1781539884:81540950:81541308:815413950.42271.9527e-022.3157e-050.4347imageNADAR;ELAVL1;UPF1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MTORC1_SIGNALING
chr3:136331287-136332088:+
THYMEERESENSG00000165113.8chr983753275:83753359:83768817:83768970:83780381:837804040.35624.7320e-027.3849e-050.4234imageNADAR;ELAVL1;UPF1NAMast_cells_restingGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr3:136331287-136332088:+
THYMEERIRENSG00000125458.2chr1775130224:75130867:75130964:75131081-0.40391.7719e-021.9646e-05-0.4381imageNELAVL1;UPF1NAMast_cells_restingGSVA_HALLMARK_NOTCH_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for PCCB


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:136331287-136332088:+ACCEERDendritic_cells_resting9.7669e-03-0.3136image
ENSG00000114054.12,PCCBACCEAGDendritic_cells_resting9.1043e-03-0.3164image
chr3:136331287-136332088:+BLCAEERT_cells_CD4_memory_activated1.8580e-030.2078image
ENSG00000114054.12,PCCBBLCAEAGT_cells_CD4_memory_activated2.2877e-030.2037image
chr3:136331287-136332088:+BRCAEERMacrophages_M11.6470e-030.1007image
ENSG00000114054.12,PCCBBRCAEAGMacrophages_M16.0231e-030.0879image
chr3:136331287-136332088:+CESCEERT_cells_CD4_memory_resting4.3714e-02-0.1421image
chr3:136331287-136332088:+CHOLEERNK_cells_activated2.5896e-020.4281image
ENSG00000114054.12,PCCBCHOLEAGNK_cells_activated2.7115e-020.4250image
chr3:136331287-136332088:+COADEERDendritic_cells_activated4.7899e-040.2490image
ENSG00000114054.12,PCCBCOADEAGEosinophils2.6759e-040.2589image
chr3:136331287-136332088:+ESCAEERT_cells_CD4_naive1.5522e-060.4290image
chr3:136334807-136335739:+ESCAEERMast_cells_resting2.6989e-020.3160image
ENSG00000114054.12,PCCBESCAEAGT_cells_CD4_naive3.9937e-020.1833image
chr3:136331287-136332088:+GBMEERMacrophages_M02.1696e-04-0.2893image
ENSG00000114054.12,PCCBGBMEAGMacrophages_M01.6235e-03-0.2480image
chr3:136331287-136332088:+KIRCEERMast_cells_activated1.9319e-02-0.1263image
ENSG00000114054.12,PCCBKIRCEAGMast_cells_activated1.5445e-02-0.1307image
chr3:136331287-136332088:+KIRPEERNK_cells_activated8.4005e-030.1586image
ENSG00000114054.12,PCCBKIRPEAGNK_cells_activated9.0871e-030.1570image
ENSG00000114054.12,PCCBLAMLEAGT_cells_regulatory_(Tregs)1.5240e-030.6342image
chr3:136331287-136332088:+LGGEERT_cells_CD4_memory_activated1.8916e-040.1622image
ENSG00000114054.12,PCCBLGGEAGT_cells_CD4_memory_activated2.5846e-030.1310image
chr3:136331287-136332088:+LIHCEERMacrophages_M02.6392e-03-0.1621image
ENSG00000114054.12,PCCBLIHCEAGMast_cells_resting1.2532e-030.1738image
chr3:136331287-136332088:+LUADEERT_cells_CD4_memory_activated8.8811e-040.1647image
ENSG00000114054.12,PCCBLUADEAGT_cells_CD4_memory_activated2.6853e-030.1490image
chr3:136331287-136332088:+LUSCEERT_cells_CD4_memory_activated8.3106e-030.1521image
ENSG00000114054.12,PCCBLUSCEAGMast_cells_activated9.7619e-030.1482image
chr3:136331287-136332088:+MESOEERDendritic_cells_activated1.5505e-030.4360image
ENSG00000114054.12,PCCBMESOEAGDendritic_cells_activated1.4302e-030.4389image
chr3:136331287-136332088:+OVEERPlasma_cells9.9421e-030.1575image
chr3:136334807-136335739:+OVEERT_cells_CD4_naive2.9638e-020.2834image
ENSG00000114054.12,PCCBOVEAGEosinophils3.8722e-030.1752image
ENSG00000114054.12,PCCBPAADEAGT_cells_CD84.4044e-02-0.1857image
chr3:136331287-136332088:+PCPGEERMast_cells_activated2.6407e-02-0.1739image
ENSG00000114054.12,PCCBPCPGEAGMast_cells_activated3.9773e-02-0.1607image
chr3:136331287-136332088:+PRADEERMast_cells_activated1.4028e-02-0.1120image
ENSG00000114054.12,PCCBPRADEAGMast_cells_activated1.4812e-02-0.1111image
chr3:136331287-136332088:+READEERMast_cells_resting3.1295e-02-0.2674image
ENSG00000114054.12,PCCBREADEAGMast_cells_resting3.5373e-02-0.2615image
chr3:136331287-136332088:+SARCEERNeutrophils2.3012e-030.2424image
ENSG00000114054.12,PCCBSARCEAGNeutrophils2.4183e-030.2404image
chr3:136331287-136332088:+SKCMEERNK_cells_activated2.8546e-030.1551image
ENSG00000114054.12,PCCBSKCMEAGNK_cells_activated2.5499e-030.1564image
chr3:136331287-136332088:+STADEERT_cells_CD4_memory_resting1.8345e-03-0.1871image
ENSG00000114054.12,PCCBSTADEAGT_cells_CD4_memory_resting6.2121e-03-0.1609image
chr3:136331287-136332088:+TGCTEERNeutrophils9.3651e-040.3198image
ENSG00000114054.12,PCCBTGCTEAGNeutrophils1.0092e-030.3164image
chr3:136331287-136332088:+THCAEERT_cells_gamma_delta1.7386e-02-0.1070image
ENSG00000114054.12,PCCBTHCAEAGT_cells_gamma_delta1.8468e-02-0.1060image
chr3:136331287-136332088:+THYMEERT_cells_follicular_helper1.1370e-02-0.2687image
ENSG00000114054.12,PCCBTHYMEAGT_cells_follicular_helper1.1214e-02-0.2692image
chr3:136331287-136332088:+UCECEERT_cells_CD4_memory_resting1.6934e-03-0.2738image
ENSG00000114054.12,PCCBUCECEAGT_cells_CD4_memory_resting1.8118e-03-0.2721image
chr3:136331287-136332088:+UCSEERMast_cells_activated2.1701e-020.3868image
chr3:136331287-136332088:+UVMEERPlasma_cells1.3392e-02-0.3230image
ENSG00000114054.12,PCCBUVMEAGPlasma_cells1.3392e-02-0.3230image


Top

6. Enriched editing regions and immune gene sets for PCCB


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000114054.12,PCCBBLCAEAG8.0854e-030.17734.1787e-030.19151.7118e-020.15993.3232e-020.1430image
chr3:136331287-136332088:+BLCAEER6.7902e-030.18124.8398e-030.18851.6162e-020.16132.6124e-020.1493image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000114054.12,PCCBACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.9121e-03-0.3218image
chr3:136331287-136332088:+ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.8565e-03-0.3174image
chr3:136331287-136332088:+BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.2632e-020.1672image
ENSG00000114054.12,PCCBBLCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.5157e-020.1628image
ENSG00000114054.12,PCCBBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4407e-090.1921image
chr3:136334807-136335739:+BRCAGSVA_HALLMARK_MYC_TARGETS_V2EER2.5052e-020.4562image
chr3:136331287-136332088:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.4786e-120.2170image
chr3:136331287-136332088:+CESCGSVA_HALLMARK_NOTCH_SIGNALINGEER2.6807e-02-0.1558image
chr3:136331287-136332088:+CHOLGSVA_HALLMARK_UV_RESPONSE_UPEER3.6994e-03-0.5393image
ENSG00000114054.12,PCCBCHOLGSVA_HALLMARK_UV_RESPONSE_UPEAG3.1681e-03-0.5467image
chr3:136331287-136332088:+COADGSVA_HALLMARK_MYOGENESISEER2.0815e-04-0.2639image
ENSG00000114054.12,PCCBCOADGSVA_HALLMARK_MYOGENESISEAG1.3893e-04-0.2702image
ENSG00000114054.12,PCCBESCAGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.4487e-030.2337image
chr3:136331287-136332088:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2111e-070.3970image
ENSG00000114054.12,PCCBGBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.9378e-070.3797image
ENSG00000114054.12,PCCBKICHGSVA_HALLMARK_APICAL_SURFACEEAG1.1093e-02-0.3155image
chr3:136331287-136332088:+KICHGSVA_HALLMARK_APICAL_SURFACEEER2.1511e-02-0.2870image
chr3:136331287-136332088:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5276e-020.1309image
ENSG00000114054.12,PCCBKIRCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.3039e-02-0.1227image
ENSG00000114054.12,PCCBLAMLGSVA_HALLMARK_SPERMATOGENESISEAG1.8372e-02-0.4979image
ENSG00000114054.12,PCCBLGGGSVA_HALLMARK_HEME_METABOLISMEAG6.0839e-080.2332image
chr3:136331287-136332088:+LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.8853e-100.2734image
chr3:136331287-136332088:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.3112e-080.2932image
ENSG00000114054.12,PCCBLIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.0980e-080.2840image
ENSG00000114054.12,PCCBLUADGSVA_HALLMARK_MYC_TARGETS_V1EAG1.3966e-050.2143image
chr3:136331287-136332088:+LUADGSVA_HALLMARK_MYC_TARGETS_V1EER2.9551e-060.2301image
chr3:136331287-136332088:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.9275e-020.1259image
chr3:136334807-136335739:+OVGSVA_HALLMARK_HEME_METABOLISMEER1.6643e-02-0.3106image
chr3:136331287-136332088:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0479e-040.2352image
ENSG00000114054.12,PCCBPAADGSVA_HALLMARK_GLYCOLYSISEAG2.6133e-030.2747image
chr3:136331287-136332088:+PAADGSVA_HALLMARK_GLYCOLYSISEER3.3091e-030.2694image
chr3:136331287-136332088:+PCPGGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.5021e-020.1653image
chr3:136331287-136332088:+PRADGSVA_HALLMARK_KRAS_SIGNALING_UPEER6.2517e-03-0.1245image
ENSG00000114054.12,PCCBPRADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG7.5029e-03-0.1218image
chr3:136331287-136332088:+READGSVA_HALLMARK_PANCREAS_BETA_CELLSEER6.1532e-03-0.3364image
ENSG00000114054.12,PCCBREADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.1209e-03-0.3308image
chr3:136331287-136332088:+SKCMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.4578e-030.1351image
ENSG00000114054.12,PCCBSKCMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.5648e-030.1386image
ENSG00000114054.12,PCCBSTADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.7503e-05-0.2444image
chr3:136331287-136332088:+STADGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER3.4906e-04-0.2141image
chr3:136331287-136332088:+TGCTGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.7845e-03-0.2596image
ENSG00000114054.12,PCCBTGCTGSVA_HALLMARK_BILE_ACID_METABOLISMEAG7.8330e-03-0.2582image
ENSG00000114054.12,PCCBTHCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.2466e-020.1027image
chr3:136331287-136332088:+THCAGSVA_HALLMARK_FATTY_ACID_METABOLISMEER3.2688e-020.0961image
ENSG00000114054.12,PCCBTHYMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.2887e-050.4273image
chr3:136331287-136332088:+THYMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER7.4223e-050.4096image
chr3:136331287-136332088:+UCECGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER9.4557e-030.2277image
ENSG00000114054.12,PCCBUCECGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG6.4581e-030.2386image
chr3:136331287-136332088:+UCSGSVA_HALLMARK_UV_RESPONSE_DNEER1.6809e-020.4015image
ENSG00000114054.12,PCCBUCSGSVA_HALLMARK_UV_RESPONSE_DNEAG1.6031e-020.3933image
ENSG00000114054.12,PCCBUVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG8.6337e-03-0.3418image
chr3:136331287-136332088:+UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER8.6337e-03-0.3418image


Top

7. Enriched editing regions and drugs for PCCB


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000114054.12,PCCBACCGSK269962AEAG1.1366e-030.3891image
chr3:136331287-136332088:+ACCGSK269962AEER8.9908e-040.3964image
ENSG00000114054.12,PCCBBLCACCT007093EAG7.0297e-030.1804image
chr3:136331287-136332088:+BLCACCT007093EER5.1432e-030.1872image
chr3:136334807-136335739:+BRCABMS.509744EER2.0863e-03-0.5967image
chr3:136331287-136332088:+BRCAJNK.Inhibitor.VIIIEER8.7773e-08-0.1704image
ENSG00000114054.12,PCCBBRCAJNK.Inhibitor.VIIIEAG5.6061e-07-0.1594image
chr3:136331287-136332088:+CESCFH535EER5.7114e-030.1938image
ENSG00000114054.12,PCCBCESCElesclomolEAG8.0326e-030.1856image
ENSG00000114054.12,PCCBCHOLDoxorubicinEAG1.6537e-02-0.4571image
chr3:136331287-136332088:+CHOLDoxorubicinEER2.2335e-02-0.4379image
ENSG00000114054.12,PCCBCOADBMS.708163EAG1.4150e-02-0.1759image
chr3:136331287-136332088:+COADBMS.708163EER3.2563e-02-0.1539image
chr3:136334807-136335739:+ESCABleomycinEER5.0679e-03-0.3942image
chr3:136331287-136332088:+ESCACCT018159EER2.4698e-03-0.2797image
ENSG00000114054.12,PCCBESCAJNK.Inhibitor.VIIIEAG3.0959e-04-0.3162image
chr3:136331287-136332088:+GBMBIBW2992EER4.2368e-04-0.2763image
ENSG00000114054.12,PCCBGBMAxitinibEAG1.4170e-040.2973image
ENSG00000114054.12,PCCBHNSCCyclopamineEAG1.2363e-02-0.1593image
chr3:136331287-136332088:+HNSCCyclopamineEER1.5437e-02-0.1552image
ENSG00000114054.12,PCCBKICHBIRB.0796EAG3.5035e-03-0.3598image
chr3:136331287-136332088:+KICHBIRB.0796EER8.0709e-03-0.3284image
chr3:136331287-136332088:+KIRCDasatinibEER2.0425e-030.1664image
ENSG00000114054.12,PCCBKIRCDasatinibEAG1.7079e-030.1693image
chr3:136331287-136332088:+KIRPAZD7762EER3.9640e-02-0.1242image
ENSG00000114054.12,PCCBKIRPAZD7762EAG4.2316e-02-0.1225image
ENSG00000114054.12,PCCBLAMLErlotinibEAG2.5618e-03-0.6102image
chr3:136334807-136335739:+LGGABT.263EER1.7098e-020.1644image
ENSG00000114054.12,PCCBLGGCamptothecinEAG2.6146e-060.2030image
chr3:136331287-136332088:+LGGElesclomolEER3.9529e-080.2369image
ENSG00000114054.12,PCCBLIHCAZ628EAG1.3582e-080.3023image
chr3:136331287-136332088:+LIHCAZ628EER5.8110e-090.3096image
ENSG00000114054.12,PCCBLUADLFM.A13EAG8.1109e-040.1660image
chr3:136331287-136332088:+LUADLFM.A13EER2.8973e-040.1794image
chr3:136334807-136335739:+LUSCAMG.706EER1.9189e-020.3886image
chr3:136331287-136332088:+LUSCAZD.2281EER1.1673e-02-0.1454image
ENSG00000114054.12,PCCBLUSCAZD.2281EAG1.2841e-02-0.1428image
chr3:136331287-136332088:+MESOBryostatin.1EER2.6703e-020.3134image
ENSG00000114054.12,PCCBMESOBryostatin.1EAG2.7526e-020.3118image
chr3:136334807-136335739:+OVAS601245EER2.2674e-030.3899image
chr3:136331287-136332088:+OVAxitinibEER7.2146e-040.2057image
ENSG00000114054.12,PCCBOVFH535EAG1.8783e-020.1429image
chr3:136331287-136332088:+PAADAZD6482EER4.8000e-030.2647image
ENSG00000114054.12,PCCBPAADAZD6482EAG4.3598e-030.2663image
chr3:136331287-136332088:+PCPGFH535EER3.5028e-02-0.1652image
ENSG00000114054.12,PCCBPCPGBIRB.0796EAG4.6108e-02-0.1560image
chr3:136331287-136332088:+PRADBX.795EER1.3612e-020.1124image
ENSG00000114054.12,PCCBPRADAP.24534EAG2.2157e-020.1043image
chr3:136331287-136332088:+SARCAKT.inhibitor.VIIIEER4.2796e-03-0.2276image
ENSG00000114054.12,PCCBSARCAKT.inhibitor.VIIIEAG3.9313e-03-0.2289image
ENSG00000114054.12,PCCBSKCMCI.1040EAG6.4513e-040.1766image
chr3:136331287-136332088:+SKCMBMS.708163EER7.1023e-030.1401image
chr3:136334807-136335739:+STADCMKEER1.2064e-02-0.3672image
ENSG00000114054.12,PCCBSTADGefitinibEAG5.3831e-03-0.1639image
chr3:136331287-136332088:+STADCCT007093EER9.5582e-03-0.1560image
chr3:136331287-136332088:+TGCTCyclopamineEER2.5695e-02-0.2187image
ENSG00000114054.12,PCCBTHCAGSK269962AEAG3.5070e-040.1604image
chr3:136331287-136332088:+THCAGSK269962AEER9.9121e-040.1479image
chr3:136331287-136332088:+THYMCEP.701EER3.5162e-060.4716image
ENSG00000114054.12,PCCBTHYMCEP.701EAG4.1979e-060.4683image
chr3:136331287-136332088:+UCECGSK269962AEER6.4107e-03-0.2388image
ENSG00000114054.12,PCCBUCECGSK269962AEAG6.8669e-03-0.2369image
ENSG00000114054.12,PCCBUCSABT.888EAG7.0357e-030.4357image
chr3:136331287-136332088:+UCSAKT.inhibitor.VIIIEER3.2727e-03-0.4833image
ENSG00000114054.12,PCCBUVMLFM.A13EAG1.3865e-020.3215image
chr3:136331287-136332088:+UVMLFM.A13EER1.3865e-020.3215image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType